Cat. No. 2373
Chemical Name: N-(2,2,2-Trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]benzenesulfonamide
Biological ActivityPotent, high affinity liver X receptor (LXR) agonist (EC50 ~ 50 nM, Kd values are 7 and 22 nM for LXR-α and LXR-β respectively). Upregulates expression of the ABCA1 gene associated with cholesterol efflux regulation and HDL metabolism. Decreases amyloid-β production in primary neurons in vitro. Displays an EC50 of ~ 5 μM for activation of bile acid farnesoid X receptors (FXRs); 10-fold more potent than natural FXR ligand chenodeoxycholic acid. Also exhibits inverse agonist activity at constitutive androstane receptors (CAR).
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Repa et al (2000) Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 289 1524. PMID: 10968783.
Houck et al (2004) T0901317 is a dual LXR/FXR agonist. Mol.Gen.Metab. 83 184.
Koldamova et al (2005) The liver X receptor ligand T0901317 decreases amyloid β production in vitro and in a mouse model of Alzheimer's disease. J.Biol.Chem. 280 4079. PMID: 15557325.
Mitro et al (2007) The nuclear receptor LXR is a glucose sensor. Nature Lett. 445 219.
Kanno et al (2013) T0901317, a potent LXR agonist, is an inverse agonist of CAR. J.Toxicol.Sci. 38 309. PMID: 23665929.
If you know of a relevant citation for this product please let us know.
Keywords: T 0901317, supplier, Potent, liver, X, receptor, LXR, agonists, FXR, Receptors, Liver, Farnesoid, LXR-like, T0901317
Find multiple products by catalog number
New Products in this Area
Prodrug of the antitumor agent 5F 203Methylprednisolone
Glucocorticoid receptor agonist(Z)-4-Hydroxytamoxifen
Metabolite of tamoxifen (Cat. No. 0999)
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.